Name | Title | Contact Details |
---|
ALB is a leading and innovative cloud and web-based platform built by industry experts and lawyers for assisting law firms across the world. ALB is an all-inclusive platform with an easy-to-use dashboard that helps the law firms timekeepers to easily capture details of their daily activities using our mobile or web app. ALB also helps the law firms billing clerk or department to easily prepare and submit accurate invoices to their clients. What makes ALB stand out from any other legal billing software is ALBs skill in being intuitive and to make corrections on line items based on a firms client SLA such that the law firms suffer zero to minimal losses on their invoice amount. Owing to ALBs latest technology, law firms can now prepare and submit invoices to clients that are 100% compliant with their clients SLA. This then results in the firms invoices being processed much faster by a legal bill review vendor or the clients in-house team. Hence the payments are processed much quicker ensuring better cashflow for the firms. Long gone are the days when legal bill vendors cause reductions to the law firms bills.
BHS Corrugated – leading provider of solutions for the corrugated industry BHS Corrugated is the leading provider of solutions for the corrugated industry with 3,000 employees at headquarters in Weiherhammer, Germany as well as in more than 20 countries. As Lifecycle Partner, BHS Corrugated is consistently strong across the entire product and service range: from development and production, to installation and maintenance, to a variety of innovative Lifecycle Service solutions in the areas of corrugating rolls, individual machines, complete corrugators, industry 4.0, logistics and soon to come digital print in- and outside the corrugator. Significant aspects of digitalization, primarily regarding the optimization of process parameters and increasing degrees of automation and production efficiency, have been central issues of BHS Corrugated for many years. To meet the requirements of its customers as precisely as possible and to be always state-of-the-art, BHS Corrugated reinvests close to 5 percent of its turnover in research and development. In addition to its core business, BHS Corrugated supports different social projects, for example the familys own foundation "Angels for Children" or the "Lars und Christian Engel Stiftung (LUCE Trust)", which supports technological and economic development in the region. Contact: BHS Corrugated Maschinen- und Anlagenbau GmbH Paul-Engel-Str. 1 92729 Weiherhammer info@bhs-world.com Tel. +49 9605 919 0 bhs-world.com
Delrin® is a highly adaptable acetal homopolymer resin that bridges the performance gap between plastics and metals and offers unique properties. Manufacturers count on Delrin® for high load mechanical applications and precision parts, where strength, stiffness, stability, and reliability are important. Applications range from gears, safety restraint components, door system, and conveyor systems components to medical delivery devices, ski bindings, zip fasteners and many others across a wide range of products and industries
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.